Individuals with GSTM1 and GSTT1 null genotypes or GSTP1-Val (105) would be expected to have decreased GST detoxification and, thus, potential increases in the levels of toxic metabolites.[13] At present, genome wide association studies have demonstrated that GSTs had been verified the crutial role in the disease onset and progression of NAFLD. The gene discussed is GSTP1; the disease is metabolic dysfunction-associated steatotic liver disease.